VOGX· Health Care› Biotechnology

Vogenx Inc

Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. More about the company

$19.08

-9.14% today

$283M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Not enough history to read yet

Setup score

—

Momentum

—

Edge

—

Is VOGX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2026-08-12 → 2026-10-22

S? 10w

2026-08-122026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 10w current

Total tracked: 10 weeks across 1 stage run.

VOGX among Biotechnology590th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…590	VOGXVogenx Inc	—	—	−29.0%

vs 52W High

—

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 11

1w13w26w

Week 11, early Stage 2

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

—

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.53x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-29.0%

—

YTD

—

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S—

Wk 11 · Vol 0.53x

2026-10-21S—

Wk 10 · Vol —x

2026-10-20S—

Wk 10 · Vol —x

2026-10-19S—

Wk 10 · Vol —x

2026-10-16S—

Wk 10 · Vol —x

2026-10-15S—

Wk 10 · Vol —x

2026-10-14S—

Wk 9 · Vol —x

2026-10-13S—

Wk 9 · Vol —x

2026-10-12S—

Wk 9 · Vol —x

2026-10-09S—

Wk 9 · Vol —x

2026-10-08S—

Wk 9 · Vol —x

2026-10-07S—

Wk 8 · Vol —x

Moving averages & range

50 DMA

$24.66

200 DMA

—

52W High

—

52W Low

—

5D Low

$14.53

Resistance levels (recent highs)

20d High

$24.32

60d High

—

120d High

—

250d High

—

Next resistance

+27.5%

to 20d High

Dividend Yield

0.00%

P/B -56.4

Vogenx: quick answers

Which sector and industry is Vogenx in?

Vogenx is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.